Trial Profile
A prospective, open-label compassionate use program in cystic fibrosis patients with non-tuberculous mycobacteria (NTM) Infection
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Aug 2019
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Cystic fibrosis; Nontuberculous mycobacterium infections
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
- 16 Jul 2018 According to an AIT Therapeutics media release, data from the compassionate use study was presented at the 3rd Annual World Bronchiectasis Conference.
- 27 Jun 2018 According to an AIT Therapeutics media release, data from compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference.